Close Menu

NEW YORK – Abbott Laboratories said Thursday that its first quarter Diagnostics business revenues declined slightly year over year.

For the three months ended March 31, Abbott reported overall Q1 revenues of $7.73 billion, up 3 percent from $7.53 billion in Q1 of 2019 and beating analysts' average estimate of $7.34 billion.

On an organic basis, revenues grew 4 percent year over year.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The US Food and Drug Administration is to announce stricter standards for emergency authorizations of SARS-CoV-2 vaccines, reports the Washington Post.

The Associated Press reports Johnson & Johnson is starting a late-stage clinical trial of its candidate SARS-CoV-2 vaccine.

Bloomberg reports the budget of Operation Warp Speed is actually $18 billion, higher than the number typically cited.

In Genome Research this week: genomic analysis reveals role of super-spreaders in SARS-CoV-2, epigenetic drivers of cancer, and more.